

Dear Editor-in-Chief

We wish to express our appreciation to the Reviewer for his insightful comments, which have helped us significantly improve the paper. We hope that our response provided below satisfactorily address all the issues and concerns you and the reviewers have noted.

**Comment:** This manuscript is an informative case report about the pneumothorax after bevacizumab use. There are 4 figures of chest CT which are perfect. As the authors indicated, this severe side effect is due to bronchopleural fistula. The incidence of serious fistulae is between <1% and 1.8% and the majority of them occurs within 6 months of first dose (reference: Bevacizumab FDA pdf). In this case, the occurrence of pneumothorax is before cycle 3, day 1, this should be approximately 4 weeks after the first dose of bevacizumab. The authors should mention the doses and schedules of Bevacizumab + Paclitaxel regimen for correct information. I recommend also correction of some minor typing errors; for ex. “Case Presentation” in place of Case Presentstion (in pp#6), “severe” in place of sever (in pp#9), “bronchopleural” in place of bronchi-pleural (in pp# 4 & 8).

**Response:** We wish to thank the reviewer for this comment. We described chemotherapy doses and schedules (P. 7 lines 19-21). We have fixed the typing errors noted.

**Comment:** The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

**Response:** We have uploaded the PowerPoint file for Figures.

**Comment:** The “core tip” section is missing. Please add the “core tip” section in front of the main text.

**Response:** It is described on page 5. We hope you can check it. Audio core tip is also uploaded.

Again, thank you for giving us the opportunity to strengthen our manuscript with your valuable comments and queries. We have worked hard to incorporate your feedback and hope that these revisions persuade you to accept our submission.

Sincerely,

Yuri Ozaki, M.D.

Department of Clinical Oncology, Aichi Cancer Center